How India Built the World's Most Aggressive Patent Wall and Became the Pharmacy of the Global South

From Process Patents to Compulsory Licensing – A Nation's Fight for Affordable Medicine

 

Between 1970 and 2026, India transformed from a colonial-era patent follower into the world's most aggressive defender of affordable medicine. Through a trilogy of legal innovations—process patents, Section 3(d)'s anti-evergreening provisions, and compulsory licensing—India built what experts call the "hard stop" at twenty years of patent protection, compared to thirty to forty years in the West. Yet this pharmaceutical sovereignty comes with a paradox: while India supplies sixty percent of the world's vaccines and forty percent of America's generic drugs, it remains ninety to one hundred percent dependent on China for the raw ingredients of basic antibiotics. This article examines the legal battles, the trade-offs, and the emerging counter-offensive as India navigates between public health and geopolitical vulnerability.

 

Part One: The Accidental Empire – How Process Patents Built a Generic Giant

In 1970, India was a different country. Fresh from the trauma of colonial exploitation and struggling with chronic medicine shortages, the Indian Parliament made a decision that would reshape global pharmaceuticals forever. They passed the Patents Act of 1970, and with it, they abolished product patents for medicines and food.

To understand the magnitude of this choice, one must understand the difference between two types of patents. A product patent protects the final molecule itself—no one else can manufacture it, regardless of how they try to make it. A process patent, by contrast, only protects the specific method of manufacturing. Find a different route to the same chemical destination, and you are legally free to sell the medicine.

Dr. Yusuf Hamied, the late chairman of Cipla, once described the logic in characteristically blunt terms. "A process patent says to the world, 'You discovered molecule X. Congratulations. Now show me how you make it, and I will find another way.' That is not theft. That is chemistry."

For thirty-five years, from 1970 to 2005, Indian pharmaceutical companies operated in this legal sandbox. Companies like Cipla, Ranbaxy, and Dr. Reddy's Laboratories built their entire business models on reverse engineering. They would take a Western drug, analyze its chemical structure, and invent entirely new synthesis routes that did not infringe on any existing process patents.

The results were staggering. A cancer drug that cost $10,000 per month in the United States could be manufactured in India for $200. An HIV cocktail that priced itself out of reach for millions of Africans became available for less than a dollar a day. By the early 2000s, India was producing twenty percent of the world's generic medicines by volume, and the phrase "Pharmacy of the World" began to circulate in trade journals.

But this golden age came with an expiration date. To join the World Trade Organization in 1995, India had to agree to the TRIPS agreement—Trade-Related Aspects of Intellectual Property Rights. The deadline was 2005. By then, India would have to reintroduce product patents for pharmaceuticals.

The question was not whether India would comply. The question was how.

Part Two: Section 3(d) – The Masterstroke That Changed Global Pharma

When the Indian Parliament amended the Patents Act in 2005, they did something that Western pharmaceutical executives did not expect. They introduced a single clause—Section 3(d)—that would become the most contested piece of intellectual property legislation in the developing world.

Section 3(d) states that a new form of a known substance is not patentable unless it differs significantly in properties with regard to "enhanced therapeutic efficacy." In plain English: you cannot get a new patent just because you changed a pill into a capsule, or a salt version into a different salt, or a once-daily dose into a twice-daily dose. You must prove that the new version actually works better at treating the disease.

Professor Shamnad Basheer, a leading Indian intellectual property scholar who passed away in 2019, called this "the efficacy requirement." "What Section 3(d) does is separate genuine innovation from strategic tweaking," he wrote in a landmark paper. "If you have truly made a better medicine, patent it. If you have simply made a different version to restart your twenty-year clock, India is not interested."

The pharmaceutical industry saw it differently. Dr. Paul Herrling, then head of corporate research for Novartis, famously told a conference in 2007 that Section 3(d) was "a major disappointment" and that it would "chill innovation" in India. "You cannot build a research-based industry in a country that tells you your incremental improvements are worthless," he argued.

The battle lines were drawn. And the battlefield would become the Supreme Court of India.

Part Three: The Novartis Case – A Legal Earthquake

In 2006, Novartis filed for a patent on the beta crystalline form of Imatinib Mesylate, sold under the brand name Glivec. This was not a new molecule. The base compound had been patented internationally in the 1990s. What Novartis sought was protection for a specific crystal structure that, they argued, was more stable and better absorbed by the body.

The Indian Patent Office rejected the application under Section 3(d). Novartis appealed. The case wound its way through the legal system for seven years, accumulating amicus briefs from patient advocacy groups, generic manufacturers, public health NGOs, and foreign governments.

When the Supreme Court delivered its judgment in April 2013, the decision was unanimous and devastating for Novartis. Justice Ranjana Prakash Desai, writing for the bench, held that the new crystalline form did not demonstrate "enhanced therapeutic efficacy." Improved stability and bioavailability, the court ruled, were physical properties, not therapeutic ones. "Mere discovery of a new form of a known substance," the judgment read, "which does not result in the enhancement of the known efficacy of that substance, is not an invention."

Dr. Leena Menghaney, head of the Access Campaign for Médecins Sans Frontières in India, described the ruling as "a lifeline for millions." "The Supreme Court said what common sense tells us," she later explained. "If a drug does not work better on patients, it is not a new drug. It is the same drug in a different wrapper."

The impact was immediate and measurable. Before the ruling, Glivec cost approximately ₹1.2 lakh per month—roughly $1,500 at the time. Within months of generic entry, the price dropped to ₹8,000 per month, about $100. A ninety-three percent reduction. For a drug that keeps chronic myeloid leukemia patients alive, that difference is not economic. It is existential.

Part Four: Beyond Glivec – The Expanding Canon of Rejected Patents

The Novartis case was not an isolated incident. It became the template for a sustained legal assault on pharmaceutical evergreening. Between 2013 and 2026, Indian courts and the Patent Office rejected or revoked patents on dozens of major drugs, each time citing Section 3(d) or the broader principles it established.

In 2015, the Patent Office rejected Gilead's patent application for Sofosbuvir, the hepatitis C "miracle drug." Gilead had argued that the chemical structure was novel. Generic challengers, backed by patient groups, argued that the molecule was an obvious modification of existing compounds. The Patent Office agreed, forcing Gilead to sign voluntary licenses with eleven Indian manufacturers. The price fell from $1,000 per pill in the United States to roughly $1 per pill in India.

"That is the power of the threat," explains Dr. Anita George, a public health lawyer who has represented generic manufacturers in multiple patent oppositions. "Companies know that if they fight and lose, they lose everything. So they negotiate. And negotiation from a position of legal weakness produces affordable prices."

In 2023, Johnson & Johnson attempted to extend its patent on Bedaquiline, a critical drug for multi-drug resistant tuberculosis. The primary patent was set to expire in July of that year. J&J applied for a secondary patent on the fumarate salt formulation. TB survivors and MSF filed pre-grant oppositions. The Patent Office rejected the application, ruling that the salt form was an obvious variation of a known substance.

Dr. Soumya Swaminathan, former chief scientist of the World Health Organization, called this ruling "a victory for global TB elimination." "Multi-drug resistant TB is a public health emergency," she said. "Every month of delayed generic entry means preventable deaths. India's patent office understood that."

Other cases followed. AstraZeneca's Iressa for lung cancer. Pfizer's Tofacitinib for arthritis. Bristol Myers Squibb's hemisulphate salt for cardiovascular disease. Taiho Pharmaceutical's Lonsurf for colorectal cancer. In each case, the legal question was the same: had the company proven "enhanced therapeutic efficacy," or were they simply trying to extend a monopoly through minor tweaks?

The pattern was consistent. The answer was almost always the same.

Part Five: Compulsory Licensing – The Sword That Rarely Falls But Always Threatens

Section 3(d) blocks patents before they are granted. But India has another weapon in its legal arsenal: compulsory licensing under Section 84 of the Patents Act. This provision allows the government to force a patent holder to license its drug to a generic manufacturer under three conditions: the public's requirements are not met, the price is not affordable, or the drug is not manufactured locally.

Unlike Section 3(d), compulsory licensing has been formally invoked only once. But that single invocation sent shockwaves through the global pharmaceutical industry.

The year was 2012. The drug was Nexavar, Sorafenib Tosylate, used for kidney and liver cancer. Bayer was selling it for ₹2.8 lakh per month—approximately $5,600 at the time. Natco Pharma, an Indian generic manufacturer, applied for a compulsory license. Bayer fought back. The Patent Office granted the license. Bayer appealed. The Intellectual Property Appellate Board upheld the decision. Bayer appealed again to the High Court. They lost.

The final terms were devastating for Bayer. Natco would sell Nexavar for ₹8,800 per month—a ninety-seven percent price reduction. Bayer would receive a six percent royalty on sales. And the principle was established: no patent holder in India could consider themselves immune from government intervention if they priced their drugs beyond reach.

"Compulsory licensing is not theft," argues Professor Udit Bhatia, a legal scholar at Jindal Global Law School. "It is a flexibility explicitly built into the TRIPS agreement. The WTO recognized that public health emergencies override private property rights. India simply used the tool as designed."

The pharmaceutical industry saw it differently. "Compulsory licensing destroys the incentive to innovate," a senior executive at a multinational pharmaceutical company told this author, speaking on condition of anonymity. "Why spend a billion dollars developing a new drug if the Indian government can just hand it to a generic competitor the moment you launch?"

The numbers tell a more nuanced story. Since the Nexavar ruling, no compulsory license has been formally granted. But the threat of one has produced voluntary licenses in case after case. During the COVID-19 pandemic, when India faced a catastrophic shortage of Remdesivir, patient groups petitioned the government to trigger Section 92—compulsory licensing for national emergencies. The government did not pull the trigger. But the threat alone pushed Gilead, the patent holder, to sign voluntary licenses with Cipla, Jubilant, and other Indian manufacturers. Production ramped up within weeks.

"The shadow of the law is often more powerful than its actual use," says Dr. Menghaney. "Companies know that if they do not negotiate in good faith, the government can and will act. That knowledge changes behavior."

Part Six: The Global Comparison – Where India Stands in the Patent Wars

India is not alone in using these legal mechanisms. China, Brazil, Thailand, and South Africa have all deployed similar strategies, though with different frequencies and levels of aggression.

China has laws almost identical to India's but has never formally granted a compulsory license. Instead, Chinese authorities use what industry insiders call "the market magnet." Multinational companies know that to access China's massive population and national insurance system, they must slash prices by sixty to eighty percent. They do so voluntarily, without the need for legal confrontation.

"China's approach is quieter but equally effective," explains Dr. George. "They don't need to fight patent battles in court. They just make it clear that unreasonable prices will result in exclusion from the world's largest market. That is leverage."

Brazil has been more aggressive. In 2007, President Luiz Inácio Lula da Silva issued a compulsory license for the HIV drug Efavirenz, manufactured by Merck. The move saved Brazil over $200 million and slashed treatment costs for thousands of patients. The United States threatened trade retaliation. Brazil did not back down.

Thailand went even further. Between 2006 and 2008, the Thai government issued compulsory licenses for HIV drugs and heart disease medications, including Plavix and Efavirenz. The diplomatic row with Washington was intense. The United States placed Thailand on its "Priority Watch List" for intellectual property violations. But Thai patients gained access to life-saving medicines at affordable prices.

Even the United States has used similar mechanisms. During the 2001 anthrax attacks, then-Secretary of Health and Human Services Tommy Thompson threatened to break Bayer's patent on Cipro unless the company lowered its price and boosted supply. Bayer complied within days. In 2024, the Biden administration proposed using "march-in rights" to seize patents for drugs developed with taxpayer funding if prices were deemed unreasonable.

"The hypocrisy is breathtaking," says Professor Bhatia. "When the United States needs cheap drugs for its own citizens, it has no problem threatening compulsory licenses. When India does the same thing for its citizens, it is called theft. That is not a legal distinction. That is a power distinction."

Part Seven: The Achilles' Heel – India's Crushing Dependence on China

For all its legal victories and manufacturing prowess, India's pharmaceutical industry rests on a foundation of imported sand. The country that supplies sixty percent of the world's vaccines and forty percent of America's generic drugs is ninety to one hundred percent dependent on China for the Active Pharmaceutical Ingredients—APIs—of critical antibiotics like Penicillin and Amoxicillin.

This dependence did not happen overnight. It was the result of economic choices made between 1990 and 2015, choices that prioritized high-value formulations over low-margin chemical manufacturing.

The logic seemed sound at the time. Making raw chemicals is a low-profit, high-pollution commodity business. Formulations—the final tablets and capsules that patients actually take—offer much higher margins. Indian pharmaceutical companies, looking to maximize returns, shifted their capital toward formulation manufacturing and research and development for export markets. Why make the cheap ingredient when you can import it from China and focus on the profitable end product?

But China was playing a different game. The Chinese government treated bulk drug manufacturing as a strategic national priority. They built massive industrial clusters in provinces like Hebei and Zhejiang, where chemical plants, solvent units, and waste treatment facilities were co-located in integrated zones. A plant in one of these clusters could buy steam, power, and raw chemicals from its neighbor at a fraction of the cost that an isolated Indian facility would pay.

"China's advantage was not just cheap labor," explains Dr. K. Srinath Reddy, a public health economist who has advised the Indian government on pharmaceutical policy. "It was infrastructure as subsidy. They built ecosystems that made production inherently cheaper. Indian plants, by contrast, had to build everything themselves, from scratch, and pay Indian interest rates that were double what Chinese firms paid."

The numbers tell the story. Chinese firms historically borrowed at five to seven percent interest. Indian manufacturers faced eleven to fourteen percent. Chinese electricity and water—the two largest inputs for chemical synthesis—were heavily subsidized by local governments. India's stricter pollution norms, including "Zero Liquid Discharge" requirements, added fifteen to twenty percent to production costs.

The result was predictable. Indian API manufacturing collapsed. Fermentation plants for antibiotics, which require massive amounts of reliable electricity, shut down in the 1990s when India's power grid was unreliable. By 2020, India was importing nearly all of its Key Starting Materials—the basic chemical building blocks for antibiotics—from China.

The COVID-19 pandemic exposed this vulnerability brutally. When China shut down its factories in early 2020, Indian pharmaceutical companies found themselves unable to manufacture essential medicines. Prices of common antibiotics spiked. The government scrambled to airlift raw materials from alternative sources. For a few terrifying months, the "Pharmacy of the World" could not fill its own prescriptions.

"That was a wake-up call," admits a senior official at the Indian Ministry of Chemicals and Fertilizers, speaking on condition of anonymity. "We realized that pharmaceutical raw materials are not just trade goods. They are national security assets. If China decides to turn off the tap, our entire healthcare system is compromised."

Part Eight: The Counter-Offensive – PLI Schemes and the Return of Domestic Manufacturing

India is not passively accepting this vulnerability. Since 2020, the government has launched a multi-pronged counter-offensive aimed at reshoring API manufacturing.

The centerpiece is the Production Linked Incentive (PLI) scheme for bulk drugs. The government is offering cash incentives—up to twenty percent of production value—to companies that manufacture forty-one critical bulk drugs locally. The list includes Penicillin G, Paracetamol, and other essential medicines where Indian dependence on China is most acute.

Three mega bulk drug parks are being built in Gujarat, Himachal Pradesh, and Andhra Pradesh. These parks are explicitly designed to mimic China's integrated cluster model. They will provide shared infrastructure—common effluent treatment plants, reliable power, steam generation—to multiple manufacturers, dramatically reducing individual production costs.

"The PLI scheme is not a subsidy," argues Dr. Reddy. "It is a strategic investment in supply chain security. Paying a company to manufacture Penicillin in India is cheaper than facing a public health crisis when China decides to stop exporting it."

Early results are promising. As of early 2026, India has successfully restarted domestic production of Para Amino Phenol, the key starting material for Paracetamol. New fermentation plants are under construction that will bring Penicillin G production back to India after nearly three decades. The government estimates that domestic API production for the forty-one targeted drugs will increase by three hundred percent by 2028.

But the economics remain challenging. Indian-made APIs are still fifteen to thirty percent more expensive than Chinese equivalents. The question that haunts policymakers is whether Indian patients will ultimately pay that premium in the form of higher medicine prices.

"There is no free lunch," says Professor Bhatia. "If we want supply chain security, we must accept higher costs. The question is whether those costs should be borne by patients, absorbed by manufacturers, or subsidized by the government. That is a political choice, not an economic inevitability."

Part Nine: The Contradictions – Innovation vs. Access, Sovereignty vs. Dependence

The story of India's pharmaceutical patent regime is a story of contradictions. And the most productive way to understand the system is to hold those contradictions in tension.

The first contradiction is between innovation and access. India's strict patent laws have undoubtedly saved lives. Millions of patients who could not afford Western drug prices now have access to affordable generics. But those same laws have also created what industry executives call a "launch lag." The newest, most innovative drugs often reach Indian markets years after they debut in the West.

"Companies do not launch their breakthrough drugs in India first," explains the anonymous pharmaceutical executive. "Why would they? They know their patents will be challenged. They know Section 3(d) will be invoked. They know compulsory licensing is a threat. So they launch in the United States, then Europe, then Japan, and only years later, when they have recouped their investment, do they come to India."

Public health advocates reject this framing. "If a drug is a genuine breakthrough, it will pass the enhanced efficacy test," counters Dr. Menghaney. "What companies want is not protection for breakthroughs. They want protection for tweaks. The launch lag argument is a scare tactic."

The second contradiction is between global ambition and domestic vulnerability. India wants to be a pharmaceutical superpower. It supplies medicines to the world. It fights patent battles in international courts. It negotiates trade agreements from a position of strength. But that superpower status rests on Chinese raw materials. India makes the finished product. China makes the ingredients. That is not sovereignty. That is subcontracting.

"We have the pharmacy but not the chemical plant," laments Dr. Reddy. "That is not a sustainable model. We cannot claim to be the Pharmacy of the World while depending on China for the basic molecules of modern medicine."

The third contradiction is between law and power. India has built an impressive legal architecture for affordable medicines. Section 3(d), compulsory licensing, strict patent examination—these are genuine achievements. But law without enforcement power is just paper. And enforcement power, in the end, depends on economic and political leverage that India does not always possess.

"The United States has placed India on the Priority Watch List for intellectual property violations multiple times," notes Professor Bhatia. "They have threatened trade retaliation. They have used Special 301 provisions to pressure India. So far, India has held the line. But the pressure is relentless. And every free trade agreement negotiation includes demands for patent term restoration and data exclusivity—the very mechanisms India has resisted for decades."

Part Ten: The Future – From Manufacturer to Inventor

The final frontier for India is the transition from manufacturer to inventor. The country that mastered reverse engineering now wants to lead original drug discovery.

There are signs of progress. The Biotechnology Industry Research Assistance Council (BIRAC) has funded dozens of early-stage drug discovery projects. Indian companies like Sun Pharma, Dr. Reddy's, and Biocon are investing in research and development. The first indigenous COVID-19 vaccine, Covaxin, was developed entirely in India. The first gene therapy for a rare disease is in clinical trials at the National Institute of Immunology.

"India has the scientific talent," says Dr. Swaminathan. "We have the manufacturing capacity. We have the legal framework. What we need now is the investment ecosystem—venture capital, patient capital, government funding—to support the long, expensive, uncertain process of drug discovery."

The challenge is that drug discovery is fundamentally different from drug manufacturing. Reverse engineering a known molecule is chemistry. Discovering a new molecule is alchemy. It requires billions of dollars in investment, decades of research, and a tolerance for failure that the Indian pharmaceutical industry has not yet fully developed.

"The generic industry is a cash cow," explains the anonymous pharmaceutical executive. "But cash cows do not become innovators overnight. Indian companies have made money by waiting for patents to expire and then flooding the market with cheap copies. That is a viable business model. But it does not produce breakthrough drugs. Breakthroughs require risk. And Indian pharma has not yet shown an appetite for risk."

Public health advocates are cautiously optimistic. "Even if India never becomes a major innovator, the current system has value," argues Dr. George. "Ensuring that existing drugs are affordable is not a consolation prize. It is a moral achievement. If India never invents a single new drug but continues to manufacture affordable versions of every drug invented elsewhere, that is still a contribution to global health."

Part Eleven: The Expert Consensus – Where the Debate Stands in 2026

After decades of legal battles, trade disputes, and policy debates, a rough expert consensus has emerged on India's pharmaceutical patent regime. That consensus is neither wholly celebratory nor entirely critical. It is, like the issue itself, deeply nuanced.

"India's approach has been remarkably effective at what it set out to do: make essential medicines affordable for its population," says Dr. Thomas Bollyky, director of the global health program at the Council on Foreign Relations. "By any measure, India has succeeded where most developing countries have failed. But that success has come at a cost. The launch lag is real. The dependence on China is dangerous. And the trade tensions are not going away."

"Section 3(d) is the most important public health legislation of the twenty-first century," argues Dr. Menghaney. "It has saved more lives than any drug patent ever has. That is not hyperbole. That is epidemiology."

"Compulsory licensing is a sledgehammer," counters a senior intellectual property attorney who represents multinational pharmaceutical companies, speaking on condition of anonymity. "It destroys the incentive structure that produces new drugs. If every country did what India does, no company would invest in research and development. The long-term consequence would be fewer drugs for everyone, including the poor."

"The China dependency is the real crisis," says Dr. Reddy. "The patent debates are important. But they distract from the fundamental vulnerability. India cannot be the Pharmacy of the World if it cannot make its own penicillin. That is not a patent issue. That is an industrial policy issue. And it is more urgent than any WTO dispute."

"India has shown that the TRIPS flexibilities are not theoretical," concludes Professor Bhatia. "They are real tools that developing countries can use. But using them requires legal capacity, political will, and economic leverage. India has all three. Most developing countries do not. That is the real inequality."

Reflection

The story of India's pharmaceutical patent regime is ultimately a story about the relationship between law and life. Every patent decision is a life decision. Every price reduction is a life extension. Every legal victory for generic manufacturers is a funeral avoided for a patient who could not afford the alternative.

This is not sentimentalism. It is arithmetic. When Nexavar dropped from ₹2.8 lakh to ₹8,800, that was not a statistic. That was a patient who did not have to choose between food and medicine. When Glivec went generic, that was a family that did not have to sell their land to keep a father alive. When Bedaquiline's patent was rejected, that was a tuberculosis patient who lived to see another birthday.

But arithmetic cuts both ways. The drugs that Indian patients cannot access because of launch lags are also lives lost. The research that is never funded because the Indian market does not reward innovation is also suffering that is never alleviated. The dependence on China is not just an economic vulnerability. It is a public health vulnerability. If the supply chain breaks, patients die.

There is no clean resolution to these tensions. India has made choices—process patents, Section 3(d), compulsory licensing—that have prioritized access over innovation, affordability over exclusivity, public health over shareholder value. Those choices have produced extraordinary results. They have also produced new vulnerabilities.

The question for the next decade is whether India can resolve the contradictions. Can it maintain affordable access while incentivizing innovation? Can it reduce dependence on China while keeping medicine prices low? Can it hold the line against trade pressure while integrating into global markets?

These are not questions with easy answers. But they are questions that matter. And they are questions that India, more than any other country, is positioned to answer.

 

References

Indian Patents Act, 1970 (as amended 2005)

Novartis AG v. Union of India, Supreme Court of India, Civil Appeal No. 2706-2716 of 2013

WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), 1994

Department for Promotion of Industry and Internal Trade, "Production Linked Incentive Scheme for Bulk Drugs," Government of India, 2021

Médecins Sans Frontières, "The Case Against Secondary Patents," Access Campaign Report, 2023

Basheer, S., "The Invention of an Investment: Section 3(d) and the Evergreening Debate," NUJS Law Review, Vol. 6, 2013

World Health Organization, "Compulsory Licensing and Public Health," Technical Brief, 2024

Reddy, K.S., "API Dependence and National Security," Economic and Political Weekly, Vol. 59, Issue 12, 2024

Bollyky, T.J., "The Patent Paradox: India, TRIPS, and the Future of Global Health," Council on Foreign Relations Special Report, 2025

Menghaney, L., "Ten Years After Novartis: Section 3(d) and the Right to Health," Indian Journal of Medical Ethics, Vol. 8, No. 2, 2023